Page last updated: 2024-12-04

clidinium

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Clidinium bromide is an anticholinergic medication used to treat gastrointestinal disorders, such as irritable bowel syndrome and peptic ulcer disease. Its synthesis involves a series of chemical reactions, typically starting with a quaternized amine and a chlorinated aromatic compound. Clidinium bromide exerts its effects by blocking the action of acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to decreased muscle spasms and reduced gastric acid secretion. It is important for its effectiveness in alleviating symptoms of gastrointestinal disorders and has been studied extensively for its efficacy and safety. It is also used in research to understand the role of the cholinergic system in various physiological processes.'

clidinium: see also record for clidinium compounds; RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

clidinium : The ester resulting from formal condensation of benzilic acid and 3-hydroxy-1-methyl-1-azoniabicyclo[2.2.2]octane. It is used, generally as the bromide, for the symptomatic treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2784
CHEMBL ID620
CHEBI ID3743
CHEBI ID95170
SCHEMBL ID14095206
MeSH IDM0154918

Synonyms (66)

Synonym
[3h](-)n-methyl-3-quinuclidinyl benzilate
(-)mqnb
(1-methyl-1-azoniabicyclo[2.2.2]octan-8-yl) 2-hydroxy-2,2-di(phenyl)acetate
[3h]clidinium
gtpl366
gtpl351
DIVK1C_000698
KBIO1_000698
SPECTRUM_000156
BSPBIO_002047
BSPBIO_000743
BPBIO1_000819
IDI1_000698
AB00053797
C07853
clidinium
7020-55-5
3-hydroxy-1-methylquinuclidinium benzilate ester
n-methyl quinuclidinyl benzilate
3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-methyl-1-azonia-bicyclo[2.2.2]octane
DB00771
PRESTWICK3_000822
PRESTWICK2_000822
KBIO2_003204
KBIO2_005772
KBIO2_000636
KBIO3_001267
KBIOGR_000842
KBIOSS_000636
PRESTWICK1_000822
SPBIO_002664
PRESTWICK0_000822
SPECTRUM3_000354
NINDS_000698
SPECTRUM4_000291
SPECTRUM2_000124
SPBIO_000168
SPECTRUM5_001529
CHEMBL620
clidinium ion
clidinium cation
L001027
3-{[hydroxy(diphenyl)acetyl]oxy}-1-methyl-1-azoniabicyclo[2.2.2]octane
CHEBI:3743
(1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate
NCGC00018171-02
1-azoniabicyclo(2.2.2)octane, 3-((hydroxydiphenylacetyl)oxy)-1-methyl-
unii-bo76jf850n
benzilic acid, ester with 3-hydroxy-1-methylquinuclidinium
quinuclidinium, 3-hydroxy-1-methyl-, benzilate (ester)
3-hydroxy-1-methylquinuclidinium benzilate (ester)
bo76jf850n ,
1-azoniabicyclo[2.2.2]octane, 3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-1-methyl-
clidinium [who-dd]
clidinium [vandf]
DTXSID6045379
3-(2-hydroxy-2,2-diphenylacetoxy)-1-methyl-1-azoniabicyclo[2.2.2]octane
HOOSGZJRQIVJSZ-UHFFFAOYSA-N
SCHEMBL14095206
AB00053797_15
2-hydroxy-2,2-diphenylacetic acid (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) ester
CHEBI:95170
(1-methylquinuclidin-1-ium-3-yl) 2-hydroxy-2,2-diphenyl-acetate
SBI-0051315.P003
Q5132472
BRD-A46066006-004-15-0

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The products formed in marketed tablet dosage forms are similar to those formed during stress studies."( Stability-indicating HPLC method for simultaneous determination of clidinium bromide and chlordiazepoxide in combined dosage forms.
Pathak, A; Rai, P; Rajput, SJ, 2010
)
0.6
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1345343Human M3 receptor (Acetylcholine receptors (muscarinic))2006British journal of pharmacology, Aug, Volume: 148, Issue:7
Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1345326Human M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
AID1345364Rat M2 receptor (Acetylcholine receptors (muscarinic))1998The Journal of pharmacology and experimental therapeutics, Feb, Volume: 284, Issue:2
Pharmacological comparison of the cloned human and rat M2 muscarinic receptor genes expressed in the murine fibroblast (B82) cell line.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (46)

TimeframeStudies, This Drug (%)All Drugs %
pre-199017 (36.96)18.7374
1990's18 (39.13)18.2507
2000's4 (8.70)29.6817
2010's6 (13.04)24.3611
2020's1 (2.17)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 81.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index81.95 (24.57)
Research Supply Index3.89 (2.92)
Research Growth Index4.40 (4.65)
Search Engine Demand Index141.47 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (81.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (2.13%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (4.26%)4.05%
Observational0 (0.00%)0.25%
Other44 (93.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study [NCT00516854]100 participants (Anticipated)Interventional2002-06-30Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]